XORTX Therapeutics (XRTX) versus Its Rivals Critical Analysis

XORTX Therapeutics (NASDAQ:XRTX) is one of 247 public companies in the “MED – DRUGS” industry, but how does it contrast to its rivals? We will compare XORTX Therapeutics to similar companies based on the strength of its analyst recommendations, earnings, profitability, institutional ownership, risk, valuation and dividends.

Institutional & Insider Ownership

0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 44.1% of shares of all “MED – DRUGS” companies are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “MED – DRUGS” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

XORTX Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, XORTX Therapeutics’ rivals have a beta of -0.50, indicating that their average stock price is 150% less volatile than the S&P 500.

Valuation and Earnings

This table compares XORTX Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
XORTX Therapeutics	N/A	-$2.66 million	-0.81
XORTX Therapeutics Competitors	$1.22 billion	$112.43 million	-0.62

XORTX Therapeutics’ rivals have higher revenue and earnings than XORTX Therapeutics. XORTX Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and price targets for XORTX Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1	0	0	0	1.00
XORTX Therapeutics Competitors	2955	4103	10419	480	2.47

As a group, “MED – DRUGS” companies have a potential upside of 123.92%. Given XORTX Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts clearly believe XORTX Therapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares XORTX Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-120.32%	-90.53%
XORTX Therapeutics Competitors	-22,403.65%	-140.28%	-22.78%

Summary

XORTX Therapeutics rivals beat XORTX Therapeutics on 10 of the 13 factors compared.

XORTX Therapeutics Company Profile

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.